Methodology

All entries for: HepaRegeniX GmbH

August 10, 2026

HepaRegeniX GmbH

Orphan Drug Designation

Tubingen
1-50 employees

treatment of frontotemporal dementia

Disease Area: Rare Diseases
Source
August 10, 2026

HepaRegeniX GmbH

Orphan Drug Designation

Tubingen
1-50 employees

prevention of post-hepatectomy liver failure

Disease Area: Rare Diseases
Source
Scroll to Top